Compare DexCom, Inc. (DXCM) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hut 8 Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Hut 8 Corp trades at $84.27 (market cap $9.82B). The key difference: DexCom, Inc. is far larger — about 3.2× Hut 8 Corp's market cap, and DexCom, Inc. is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Hut 8 Corp for 11 Days on average.
| DXCM | HUT | |
|---|---|---|
Market Cap | $31.86B | $9.82B |
Volume | 3,607,070 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $92.34 | $133.02 |
52-Week Low | $54.84 | $33.76 |
Typical Hold Time | 62 Days | 11 Days |
Enterprise Value | $31.32B | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
HUT trades at $79.59, down 10.87% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -188.59% net income margin and has missed earnings expectations for three consecutive quarters. Recent positive developments include securing a $1.07 billion credit facility and growing institutional interest, positioning the company in the expanding AI infrastructure market.
While analyst consensus remains strongly bullish with a $162.69 price target, significant risks persist including ongoing losses, high valuation multiples, and competitive pressures in AI infrastructure. The stock's outlook hinges on successful execution of its business transformation and achieving profitability amid substantial capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
